Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Portfolio Pulse from
Astellas Pharma and Sangamo Therapeutics have entered a license agreement for Sangamo's STAC-BBB capsid, aimed at developing genomic medicines for neurological diseases. Sangamo will receive a $20 million upfront fee and could earn up to $1.3 billion in milestone payments.
December 19, 2024 | 7:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sangamo Therapeutics has entered a licensing agreement with Astellas Pharma for its STAC-BBB capsid, receiving $20 million upfront and potential milestone payments up to $1.3 billion.
The agreement provides Sangamo with immediate financial benefits and potential future revenue through milestone payments and royalties, likely boosting investor confidence and stock price.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90